药明生物-亚洲医疗行业考察要点

China (PRC) | Pharmaceutical Svcs. Asia Healthcare Tour Takeaways We recently visited WuXi Bio during our Grand Asia Healthcare Tour during Sep 17-26. Below are the key takeaways with full transcript of our Q&A with management. Despite heightened US-China tensions and the Biosecure Act debate, WuXi expects no direct impact - its name was absent from recent legislative drafts, and the House version stalled. The company remains confident in its compliance and quality track record, with FDA and EMA approvals a ...